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Prodynorphin Mutations Cause the Neurodegenerative
Disorder Spinocerebellar Ataxia Type 23
Georgy Bakalkin,1 Hiroyuki Watanabe,1,10 Justyna Jezierska,2,10 Cloe¨ Depoorter,2
Corien Verschuuren-Bemelmans,2 Igor Bazov,1 Konstantin A. Artemenko,3 Tatjana Yakovleva,1
Dennis Dooijes,4 Bart P.C. Van de Warrenburg,5 Roman A. Zubarev,6 Berry Kremer,7 Pamela E. Knapp,8,9
Kurt F. Hauser,9 Cisca Wijmenga,2 Fred Nyberg,1 Richard J. Sinke,2,4 and Dineke S. Verbeek2,*
Spinocerebellar ataxias (SCAs) are dominantly inherited neurodegenerative disorders characterized by progressive cerebellar ataxia and
dysarthria. We have identified missense mutations in prodynorphin (PDYN) that cause SCA23 in four Dutch families displaying progres-
sive gait and limb ataxia. PDYN is the precursor protein for the opioid neuropeptides, a-neoendorphin, and dynorphins A and B (Dyn A
and B). Dynorphins regulate pain processing and modulate the rewarding effects of addictive substances. Three mutations were located
in Dyn A, a peptide with both opioid activities and nonopioid neurodegenerative actions. Two of these mutations resulted in excessive
generation of Dyn A in a cellular model system. In addition, two of the mutant Dyn A peptides induced toxicity above that of wild-type
Dyn A in cultured striatal neurons. The fourth mutation was located in the nonopioid PDYN domain and was associated with altered
expression of components of the opioid and glutamate system, as evident from analysis of SCA23 autopsy tissue. Thus, alterations in
Dyn A activities and/or impairment of secretory pathways by mutant PDYN may lead to glutamate neurotoxicity, which underlies
Purkinje cell degeneration and ataxia. PDYN mutations are identified in a small subset of ataxia families, indicating that SCA23 is an
infrequent SCA type (~0.5%) in the Netherlands and suggesting further genetic SCA heterogeneity.Introduction
The dominant spinocerebellar ataxias (SCAs) are a geneti-
cally heterogeneous group of neurodegenerative disorders
characterized by progressive cerebellar ataxia, dysarthria,
oculomotor abnormalities, and many additional symp-
toms.1 The ataxia results from selective atrophy of the Pur-
kinje cells in the cerebellum. To date, 31 different SCA loci
have been described, but the causativemutation and corre-
sponding gene has only been identified in 19 SCA types.2,3
Nine of the 19 SCAs are caused by coding CAG repeat
(SCA1–3, SCA6, SCA7, and SCA17; MIM #164400, MIM
#183090, MIM #109150, MIM #183086, MIM #164500,
and MIM #607136) or noncoding CAG, CTG, or ATTCT
repeat expansions. These coding CAG (glutamine) repeat
expansions lead to elongated polyglutamine tracts that
subsequently cause misfolding of the corresponding pro-
teins. The functional implication of the noncoding repeat
expansions is suggested to induce RNA-mediated gain-of-
function mechanisms, leading to neurotoxicity. How-
ever, the remainders of the known SCA types are due
to missense mutations or chromosomal rearrangements
(SCA5, SCA11, SCA13–15, SCA20, SCA27, SCA28, and
SCA31; MIM #600224, MIM #604432, MIM #605259,
MIM #605361, MIM #606658, MIM #608687, MIM1Division of Biological Research onDrug Dependence, Department of Pharmac
ment of Genetics, University Medical Center Groningen, University of Groni
Analytical Chemistry, Uppsala University, SE-75123 Uppsala, Sweden; 4Depa
Utrecht, The Netherlands; 5Department of Neurology, University Medical Cen
Biometry, Department of Medicinal Biochemistry and Biophysics Departme
Neurology, University Medical Center Groningen, University of Groningen, 9
biology, Virginia Commonwealth University, Richmond, VA 23298, USA; 9Depa
Studies, Virginia Commonwealth University, Richmond, VA 23298, USA
10These authors contributed equally to this work
*Correspondence: d.s.verbeek@medgen.umcg.nl
DOI 10.1016/j.ajhg.2010.10.001. 2010 by The American Society of Human
The American#609307, MIM #610246, and MIM #117210).2 The SCA
genes involved play a role in a wide range of biological
processes. Recent studies into the function of the disease
proteins revealed the existence of common pathways
leading to ataxia consisting of changes in gene transcrip-
tion and RNA processing or synaptic transmission via
calcium and glutamate signaling.4,5
Currently, only 70% of the Dutch SCA families can be
diagnosed by mutation analysis of seven of the known
SCA genes (SCA1–3, SCA6, SCA7, SCA12, and SCA14).
The identification of causal mutations and novel genes in
the group of genetically undiagnosed families will provide
additional insights into the underlying pathological path-
ways leading to cerebellar neurodegeneration and will
perhaps indicate therapeutic approaches.
We previously mapped the SCA23 locus (MIM #610245)
to a 6 Mb region located on chromosomal region 20p12.3-
p13 in a single, large Dutch ataxia family without
mutations in the SCA genes that were recognized at the
time.6 MRI and neuropathological examination of SCA23
autopsy tissue revealed neuronal loss in the Purkinje cell
layer, dentate nuclei, and inferior olivary nuclei. The
patients showed a relatively slowly progressive, isolated,
cerebellar ataxia. Additional neurological examination
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saccades, and ocular dysmetria. Decreased vibration sense
below the knee was observed in three affected individuals,
hyper-reflexia was observed in four patients, and two
patients displayed Babinski’s signs. Because no affected
individuals of the first generation were still alive at the
time of the assessment, clinical anticipation could not be
confirmed. The SCA23 locus comprises 97 genes and tran-
scripts, of which at least 54 are expressed in the cere-
bellum. Previous attempts to identify one or more muta-
tions causing the disease did not yield any results.6,7
In the present study, we identified four missense muta-
tions in prodynorphin, PDYN (MIM #131340), in the origi-
nally reported SCA23 family and in three families from
a Dutch ataxia cohort. PDYN is the precursor protein for
the opioid neuropeptides a-neoendorphin, Dyn A, and
Dyn B, ligands for the k-opioid receptor (OPRK1; MIM
#165196).8 Neuropeptides constitute a large family of
signaling molecules that mediate and modulate neuronal
communication by acting on cell surface receptors and
thus regulate diverse physiological functions and behav-
ior.9,10 Neuropeptides and their precursor molecules have
not yet been identified as causative factors for neurodegen-
erative disorders.Subjects and Methods
Human Subjects
The participants from the SCA23 family all gave informed
consent, as approved by the Medical Ethical Committee of the
University Medical Centre Utrecht. The 1100 ataxia patients
(single index cases) screened in this study were obtained from
the genetic diagnostic centers in Utrecht and Groningen in The
Netherlands. All extended DNA analyses were performed in
a diagnostic setting (accredited diagnostic DNA laboratory).
Only DNA samples from patients who were referred for genetic
testing for SCA were used and had no mutations in seven known
SCA (SCA1–3, SCA6, SCA7, SCA12, and SCA14) genes. This
cohort is comprised of 10% familial cases (8% dominant and
2% recessive) and 90% seemingly sporadic cases. The additional
tests were thus performed in line with the original diagnostic
request. Moreover, when the blood samples were taken, patients
were asked whether they had objections to the use of their DNA
for future (anonymous) studies to help develop or improve tech-
niques. If they had objections, this was indicated on the original
‘‘Request for DNA Test’’ form, and the DNA was not used. The
unrelated 500 control individuals were obtained from the Dutch
blood bank.
Postmortem Human Specimens
SCA23 cerebellar tissues from the subject with a p.R138Smutation
and from a control subject were obtained from the University
Medical Center Nijmegen, Nijmegen, The Netherlands. Samples
of the cerebellum (Cb), dorsolateral prefrontal cortex (PFC; Brod-
mann area 9), and nucleus accumbens (NAc) from three control
subjects, all females of European descent (for demographic data,
see Table S6 available online), were collected at the Karolinska
Institute, Stockholm, Sweden, by qualified pathologists. The
collection was performed under full ethical clearance from the
University Medical Center Nijmegen and the Stockholm Ethical594 The American Journal of Human Genetics 87, 593–603, NovembReview Board. Informed written consent from the next of kin
was also obtained.
PDYN Sequencing
DNA was extracted from peripheral blood by a routine salting-out
procedure. The genomic DNA of all participating subjects in
this study was used to amplify the PDYN coding exons 3 and 4
(GenBank accession number: NM 024411.3) by PCR. The resulting
amplicons, including the intron-exon boundaries, were screened
for mutations via Sanger sequencing on an ABI 3700 (Applied Bio-
systems). The PCR, primer sequences, and conditions are shown in
Table S7.
Dynorphin Radioimmunoassay
The radioimmunoassay (RIA) procedure was described else-
where.11,12 Briefly, cells were extracted in 1 M acetic acid, extracts
were run through an SP-Sephadex ion exchange C-25 column, and
peptides were eluted and analyzed by RIA.
Peptide Synthesis
Dyn A peptides were synthesized at the Leiden University Medical
Center, Leiden, The Netherlands, purified by reverse-phase chro-
matography and Superdex column, and analyzed by reverse-phase
chromatography and MALDI-TOF MS. The purity of all peptides
was ~98%.
Neuron-Enriched Cultures, Peptide Treatment,
and Assessment of Neuron Viability
Neurons were isolated from E15–E16 imprinting control region
CD-1 mouse striatum as published.13 Briefly, the tissue was enzy-
matically and mechanically dissociated and filtered through a
70 mm pore nylon mesh. Neurons were plated onto poly-L-lysine
(Sigma-Aldrich) coated glass coverslips inserted into a 24-well mul-
tiwell plate (5 3 105 neurons suspended per well). Neurons were
maintained in Neurobasal media with added B27 supplement
(Invitrogen), antibiotics, 0.5 mM L-glutamine, and 0.025 mM
glutamate (both Invitrogen) at 37C in 5%CO2 at ~95% humidity.
Cultures matured for 1 week prior to the start of experiments and
were almost exclusively neurons when assessed by immunostain-
ing for either NeuN or MAP2a/b (glial contamination < 1%).
Neurons were treated with wild-type or mutant Dyn A peptides
(p.L211S, p.R212W, or p.R215C) at 100 nM for 60 hr.
Time-lapse digital images of the same neuron were recorded at
20 min intervals for 60 hr with a Zeiss AxioObserver Z.1 micro-
scope equipped with an automated, computer-controlled stage
encoder, digital camera (Zeiss MRm), and environmental control
chamber (PeCon Instruments) at 37C with 95% humidity and
5% CO2. In each experiment, cells from 2–3 pups were pooled
and distributed across treatments such that the neurotoxic effects
of each peptide variant were directly compared in the same popu-
lation of cells. Approximately 50 healthy neurons with well-
defined dendritic and axonal arbors were identified within R8
overlapping fields (403 magnification; Mark&Find and Time
Lapse modules Zeiss AxioVision 4.6) in each individual culture
well prior to treatment (0 hr). Individual neurons were tracked
throughout the experiment, and death was defined by the culmi-
nation of a series of events resulting in nuclear fragmentation and
destruction of the cell body. Events preceding neuronal death
included dendritic and axonal pruning, the dissolution of the
Nissl substance, appearance of cytoplasmic swelling and vacuoli-
zation, nuclear damage and pyknosis, and eventual destructioner 12, 2010
of the cell body.13,14 Death was confirmed by viability markers
such as ethidium homodimer, ethidium monoazide, or trypan
blue (data not shown). These markers all possess inherent cytotox-
icity and cannot be used to monitor cells during the entire
course of the experiment. The effect of each treatment on neuron
survival (percent pretreatment value) was analyzed statistically
at 4 hr intervals via one-way repeated-measures analysis of vari-
ance (ANOVA; Graphpad Prism software) and was reported as
mean neuron survival 5 standard error of the mean (SEM) from
n ¼ 2–4 separate experiments (100–200 total neurons per
treatment).
mRNA Analysis By Quantitative Real-Time PCR
with TaqMan Low-Density Arrays
RNA preparation was performed with RNeasy Lipid TissueMini Kit
(QIAGEN). RNA was quantified with microspectrophotometry by
Nanodrop. RNA Quality Indicator (RQI) was measured with Bio-
Rad Experion. RNA samples with RQI values above 5.0 are gener-
ally considered to be suitable for qRT-PCR.15–17 Average RQI was
7.28 5 1.55 (mean, standard deviation [SD]), demonstrating
high quality of isolated RNA. cDNA was synthesized with the
High-Capacity cDNA Archive Kit (Applied Biosystems). mRNA
levels were quantified by TaqMan low-density arrays (Applied Bio-
systems). For each gene, every sample was run in triplicate on the
same array. To measure the quantity of a given RNA species, we
monitored the threshold cycles (Ct) by the Applied Biosystems
7900HT Fast Real-Time PCR System. mRNA levels were calculated
by relative quantification by using a normalization factor
(geometric mean of four reference genes: beta-actin, ACTB; ribo-
somal large P0, RPLP0; polymerase (RNA) II [DNA-directed) poly-
peptide A, POLR2A; and ubiquitin C, UBC) and the qBASE program
for internal and external calibration and for easy care of large
RT-PCR data sets.
Immunohistochemistry
The cerebellar tissue was obtained from an SCA23 patient with
a p.R138S6 and from a control subject via a rapid autopsy protocol
with a warm postmortem interval of 4 or 5 hr (Table S4). The
control subject was without cerebellar ataxia or other neurological
disorders. Fresh-frozen cerebellar tissue samples were fixed in 4%
phosphate-buffered paraformaldehyde, frozen, cut in 5 mm thick
sections, and processed as described previously, with modifica-
tions.18,19 Briefly, the sections were incubated with PBS/0.2%
triton and 0.1 M sodium citrate buffer (pH ¼ 4.5) exposed to
microwave irradiation and incubated with rabbit polyclonal
anti-PDYN, Dyn A, or Dyn B antibodies (IgG fraction)12,19 or
mouse monoclonal anti-SLC1A6 (alias EAAT4; MIM #600637)
antibodies (Abcam). After incubation with peroxidase-labeled
secondary antibodies (Santa Cruz Biotechnology), the staining
was visualized by 3-amino-9-ethylcarbazole (AEC; Sigma-Aldrich)
and counterstained with hematoxylin. The sections were analyzed
with a bright-field microscope (Leica; DM3000).
Cell Culture, Transfection, and Plasmids
RINm-5F cells were grown in RPMI-1960 (Invitrogen) supple-
mented with 10% fetal bovine serum (Invitrogen) in a 37C
incubator with 5% CO2. Transfections were carried out with Lipo-
fectamine (Invitrogen). pCMV4 empty plasmid was used for mock
transfection. The wild-type pCMV4-fl-h-PDYN construct was
described previously.19 The p.R138S, p.L211S, p.R212W, and
p.R215C mutations were introduced into the PDYN cDNA withThe Americanthe Quickchange II Site-Directed Mutagenesis kit (Stratagene).
The mutagenesis primers that were used to generate the mutant
PDYN constructs are listed in Table S8. Sequencing was performed
to verify the presence of the mutations and to check PDYN cDNA
sequence.
Western Blotting
To enrich PDYN in extracts of the cerebellum characterized by low
PDYN expression levels, we extracted the tissues with 1 M acetic
acid followed by SEP-PAC C18 reverse-phase chromatography or
with Buffer C, as described before.12,19 Both procedures gave essen-
tially the same results. Tissues for analysis of EAAT4 and calbindin
(MIM #114050) and cell pellets for analysis of PDYN were
extracted with 4% SDS buffer supplemented with DTT and Com-
pete Inhibitor Cocktail (Roche), as described previously.20 Protein
concentration was determined with DC protein assay (Bio-Rad
Laboratory). Proteins were resolved by SDS-PAGE on 10% Tricine
gels, transferred onto nitrocellulose membranes (Schleicher and
Schuell), and stained with MemCode reversible Protein Stain Kit
(Pierce), as described previously.12,19 Membranes blocked with
5% nonfat dry milk were probed with anti-PDYN, anti-Dyn B,
and anti-EAAT4 antibodies (Santa Cruz Biotechnology) or anti-
calbindin antibody (Sigma-Aldrich) and were incubated with
peroxidase-conjugated anti-rabbit, anti-mouse (Bio-Rad Labora-
tory), and anti-goat secondary antibodies (Sigma-Aldrich). Densi-
tometric analysis was performed with Image Gauge V3.12
(Fujifilm). Protein levels were calculated as the ratio of optical
density (OD) of protein immunoreactivity to MemCode OD.
Measurements of all proteins were performed within the linear
range of detection. The correlation coefficient between protein
immunoreactivity measured as OD and protein load measured as
MemCode OD was 0.98 or higher.
Sample Preparation for Mass Spectrometry Analysis
Powdered brain tissue samples were sonicated in the extraction
buffer (6 M urea, 2 M thiourea, and 1% octyl-b-D-glucopyranoside
[all Sigma-Aldrich] in 10 mM Tris-HCl) and further exchanged
to 50 mM NH4HCO3 (Sigma-Aldrich) with PD SpinTrap G-25
columns (GE Healthcare). The protein was measured via the mi-
croBCA assay (Pierce). The samples were processed via a modifica-
tion of protocol described elsewhere.21 The samples were reduced
with 15 mM 1,4-dithiothreitol (Roche), alkylated by incubation
with 30 mM iodoacetamide (Sigma-Aldrich), and then processed
on the 10 kDa cutoff filters (Millipore). Stepwise washing with
2% acetonitrile (Sigma-Aldrich) in 50 mM NH4HCO3, 50% aceto-
nitrile in 50 mM NH4HCO3 and 50 mM NH4HCO3 was followed
by incubation with trypsin (1 mg per 50 mg protein; Roche) for
20 hr at 37C. Peptides were eluted from the filters with 0.1% for-
mic acid (Sigma-Aldrich) andwere dried on SpeedVac. The aliquots
of each sample containing the same amount of protein (3 mg) were
prepared by dilution in 0.1% trifluoroacetic acid.
High-Performance Liquid Chromatography/Tandem
Mass Spectrometry and Key-Node Analysis
Experiments were performed on an LTQ-FT Ultra mass spectrom-
eter (ThermoFisher Scientific) used online with an Agilent 1100
nanoflow high-performance liquid chromatography and a nano
electrospray ion source (Proxeon Biosystems). A 15 cm C18 nano-
column (75 mM inner diameter, 375 mm outer diameter) was used
for peptide elution at a flow of 200 nL/min with a gradient from
2% to 50% acetonitrile for 100 min. Mass spectrometric analysisJournal of Human Genetics 87, 593–603, November 12, 2010 595
was performed by recording of high-resolution (100,000) survey
mass spectrum in Fourier transform mass spectrometry and
consecutive low-resolution, collision-induced dissociation of up
to five of the most abundant ions in the LTQ. Acquired data
(.RAW files) were converted to the Mascot search engine (version
2.1.3, Matrix Science). Monoisotopic mass tolerance was set to
10 ppm, and for fragment ions it was 50.9 Da. A protein was
considered to be positively matched by using the stringent
threshold of 27 for the Mowse score for all its peptides (p %
0.05). The Mascot htm output and .RAW files of each sample
were used as input files for quantification with an in-house-
written program package (Cþþ). The area of the chromatographic
peak was taken as the peptide abundance. Sum of the abundances
of all ‘‘bold red’’ nonidentical peptides was attributed to the
protein expression level (R1 peptide per protein). Protein expres-
sion data are shown in Table S4. Protein IDs and protein abun-
dances were loaded into ExPlain 2.4.1 tool (BIOBASE GmbH),
where protein IDs were substituted by respective gene IDs. Then
we searched upstream for the key nodes most relevant for the
input gene products.22 Key nodes are signaling molecules found
on pathway intersections in the upstream vicinity of the genes
from the input list. Each key node found was given a score reflect-
ing its connectivity, i.e., how many input-list genes are reached
and the proximities to those genes. The score calculation also
included the abundances of the downstream proteins. Changes
in the key node scores thus reflected the changes in the activation
levels of the corresponding signaling networks.22Results
We previously reported the mapping of the SCA23 locus
to chromosomal region 20p12.3-p13.6 After excluding
32 prioritized genes via sequencing,7 we identified a
c.414G>T (p.R138S) transition resulting in a missense
mutation in exon 4 of PDYN in all affected familymembers
(n ¼ 10), but not in unaffected relatives (n ¼ 4) of the orig-
inally reported SCA23 family (Figures 1A and 1B). To con-
firm a possible role of PDYN in cerebellar degeneration, we
screened the coding region of PDYN in a panel of Dutch
ataxia patients (n ¼ 1100). The panel consists of ataxia
patients who applied for regular DNA diagnostics and
had no mutations in seven known SCA genes (SCA1–3,
SCA6, SCA7, SCA12, and SCA14). Only in 10% of these
cases was a clear familial history of the disease described
(8% dominant and 2% recessive), and 90% seemed appar-
ently sporadic.
We identified three additional missense mutations,
c.632T>C (p.L211S), c.634C>T (p.R212W), and c.643C>T
(p.R215C), among the 1100 screened Dutch ataxia patients
(one familial case with dominant inheritance of the disease
and two apparently sporadic cases with an unknown
family history; Figures 1C–1E). We were able to show segre-
gation of the p.R215C substitution in two affected siblings
(patients II-1 and II-2 in Figure 1E). For the other two fami-
lies (Figures 1C and 1D), no additional family members
were available. The man with the p.L211S mutation
(Figure 1C, patient II:3) suffered from progressive gait
and upper limb ataxia, oculomotor abnormalities, distal596 The American Journal of Human Genetics 87, 593–603, Novembsensory neuropathy, and pyramidal signs of the legs. In
addition, subtle parkinsonian features were noted. The
disease symptoms started at age 73. The family history
was incomplete, and ataxia was not mentioned. The
woman with the p.R212W mutation (Figure 1D, patient
II:3) displayed a slowly progressive cerebellar ataxia of
the legs and arms, as well as a progressive mixed axonal
polyneuropathy. The onset of the symptoms started at
age 54, and the family history was negative for ataxia.
An MRI scan of the brain, performed 4 months prior to
death, revealed generalized cerebral cortical and subcor-
tical atrophy, agenesis of the corpus callosum, and promi-
nent atrophy of the cerebellar vermis, the pons, and
the inferior olivary nucleus. The woman carrying the
p.R215C mutation (Figure 1E, patient II:1) was initially
diagnosed with an essential tremor of head and postural
arms. From about age 50 onward, memory and word find-
ing deteriorated. A neurological exam at age 53 revealed
slowed mental processes, slight dysarthria, mild ataxia of
upper and lower limbs, postural arm tremor and a tremor
of the head, proximal paresis of the legs with mild signs
of sensory neuropathy, and a bilateral pes cavus. Her
brother (Figure 1E, patient II:2) was already considered
clumsy at school age. Around age 54, mild gait impairment
and slowing were noted. The neurological examination at
age 56 revealed head tremor, fixation instability at neutral
gaze, very mild dysarthria, action tremor of the hands,
and a subtle ataxia of the hands and arms. The mother of
these two patients (not examined by us) suffered from
mild late-onset ataxia and head and limb tremor since
primary school, and her mother likely suffered from
dementia. The clinical details are summarized in Table S1.
All four mutations were absent in 1000 Dutch blood bank
control chromosomes. In addition, three known SNPs
(rs77155664, rs45469293, and rs6045819) were identified
in exon 4, and no difference in their distribution was
observed between ataxia cases and controls (data not
shown).
Of the four altered amino acids, Arg138 is confined to
humans (Figure 1F), whereas Lys211, Arg212, and Arg215
were conserved across the vertebrate species examined
(Figures 1G and 1H). In silico analysis with four different
bioinformatics programs (polyPhen, SIFT, SWAP, and Align
GVD) predicted three (p.L211S, p.R212W, and p.R215C)
of the four missense mutations to have damaging effects
on protein structure and function, whereas the p.R138S
mutation was predicted to be benign (Table S2). In addi-
tion, the p.R138S and p.L211S mutations were also pre-
dicted to increase PDYN phosphorylation levels by gener-
ating potential phosphorylation sites (Table S3).
Proprotein convertases 1 and 2 cleave PDYN at both
paired and single basic residues, resulting in defined
sets of neuropeptides.8,23 The human-specific Arg138 is
located in the nonopioid domain of PDYN and may
affect N-terminal trimming of the 8 kDa and 10 kDa
PDYN processing intermediates. The p.L211S, p.R212W,
and p.R215C mutations in PDYN substitute amino acider 12, 2010
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Figure 1. PDYN Mutations Causing SCA23
(A) PDYN exons 3 and 4 encode PDYN, which gives rise to the opioid peptides a-neoendorphin (a-NE), dynorphin A (Dyn A), dynorphin
B (Dyn B), and big dynorphin (Big Dyn), which encompasses Dyn A and Dyn B. DNA sequence analysis identified four missense muta-
tions (c.414G>T, c.632T>C, c.634C>T, and c.643C>T) in SCA23 subjects.
(B) Sequence electropherogram and pedigree of original Dutch SCA23 family. The c.414G>T; p.R138S mutation was identified in
10 affected individuals, but not in the four unaffected family members.
(C–E) Sequence electropherograms and pedigrees of the patients with Dyn A mutations: c.632T>C; p.L211S, c.634C>T; p.R212W, and
c.643C>T; p.R215C. At themoment, noDNAmaterial of additional familymembers was available formutation screening in the p.L211S
and p.R212W families. The p.R215C mutation was identified in two affected siblings. Closed symbols denote affected; open symbols
denote unaffected; ? denotes disease status unknown; / denotes deceased.
(F and G) Conservation of the mutated amino acids. Arginine 138 is human specific; other species analyzed have glycine 138. Leucine
211, Arginine 212, and Arginine 215 are conserved across species.
(H) Localization of mutations in Dyn A.
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Figure 2. SCA23 Mutations Affect PDYN Pro-
cessing and Enhance Dyn A Toxicity
(A) Expression and processing of WT and mutant
PDYNs in RINm-5F cells. Immunoblotting was
performed with anti-PDYN (against C-terminal
fragment; top) or anti-Dyn B (bottom) anti-
bodies. Synthetic big dynorphin (a 32 amino
acid peptide consisting of Dyn A and Dyn B)
and Dyn Bwere loaded on the same gel as peptide
markers and produced the 4 and 2 kDa bands
identified by anti-Dyn B antibodies (data not
shown; however, their positions are shown on
the right). The 10, 4, and 2 kDa PDYN processing
products were detected in RINm-5F cells trans-
fected with PDYN expression plasmids.
(B–D) Peptide levels in cells expressingWT PDYN
were taken as 100%. One-way ANOVA followed
by Dunnett’s multiple comparison test; **p <
0.01, ***p < 0.001; mutant versus wild-type.
Data are shown as means5 SEM.
(B) RINm-5F cells expressing PDYN p.L211S and
p.R212W showed significant elevation in levels
of Dyn A compared to cells expressing WT
PDYN (ANOVA; p < 0.001). The Dyn A RIA was
not hindered by the mutations because they did
not affect the binding of the mutant peptides to
the Dyn A antibodies. The antibodies were gener-
ated against the C-terminal Dyn A fragment.12,19
(C) Dyn B levels showed significant decrease in
cells expressing PDYN p.R138S, p.R212W, and
p.R215C (ANOVA; p < 0.001).
(D) PDYN p.R138S and p.R215C produced lower
levels of Leu-enkephalin-Arg compared to WT
PDYN (ANOVA; p < 0.005). Leu-enkephalin-
Arg peptides derived from PDYN p.L211S and
p.R212W were not analyzed by RIA because
these two mutations are located within the
Leu-enkephalin-Arg antigenic epitope and may
hinder the binding of these mutant peptides to
anti-Leu-enkephalin-Arg antibodies.12,19
(E and F) Time-lapse imaging of striatial neurons
treated with Dyn A peptides (100 nM) revealed
marked loss of neuronal viability induced by
Dyn A p.R212W and Dyn A p.R215C peptides
compared to vehicle-treated control or WT
Dyn A (one-way repeated-measures ANOVA; p <
0.005). Data are represented as themeans5 SEM.
(F) Neuronal death at 60 hr induced by mutant Dyn A peptides. The level of neuronal death as a result of excess WT Dyn A was
considered as 1. Bonferroni’s multiple correction test, *p < 0.05. Data are represented as the means5 SD.residues Leu5, Arg6, and Arg9 to Ser5, Trp6, and Cys9,
respectively, in the 17 amino acid Dyn A sequence
(Figure 1H). These changes may abrogate Dyn A conver-
sion to Dyn A(1–8), Leu-enkephalin-Arg, or Leu-enkeph-
alin; Dyn A is cleaved between the 8th and 9th, 6th and
7th, and 5th and 6th amino acid residues, and both Arg6
and Arg9 are critical for Dyn A processing.
23,24
To examine whether the mutations affect PDYN
synthesis and processing, we transfected the cDNA wild-
type (WT) or mutant PDYN cDNA into rat insulinoma
RINm-5F cells. Protein and peptide products were analyzed
by immunoblotting with anti-PDYN and Dyn B antibodies
and by RIA for Dyn A, Dyn B, and the dynorphin con-
version product Leu-enkephalin-Arg (Figures 2A–2D).19
RINm-5F cells do not produce endogenous PDYN and effi-
ciently process ectopic PDYN into opioid peptides.19 Anal-598 The American Journal of Human Genetics 87, 593–603, Novembysis of cells transfected with PDYN plasmids demonstrated
that WT and all mutants produced the 28 kDa PDYNs at
similar levels (Figure 2A). However, the efficiency of pro-
cessing of these proteins to opioid peptides was dramati-
cally affected by the mutations (Figures 2B–2D). The levels
of Dyn A produced by PDYN p.L211S and p.R212W were
10- to 18-fold elevated compared toWT, whereas the levels
of Dyn B produced by PDYN p.R138S, p.R212W, and
p.R215C, as well as the levels of Leu-enkephalin-Arg
produced by PDYN p.R138S and p.R215C, were decreased
approximately 2-fold. Thus, all three Dyn A mutants
resulted in a 2- to 35-fold higher Dyn A production
compared to Dyn B.
Previous studies have shown that Dyn A can induce
toxicity and neuronal cell death.25–27 To examine whether
mutant Dyn A would be more neurotoxic, we analyzeder 12, 2010
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Figure 3. Impact of the PDYN p.R138S Muta-
tion on Expression of the Opioid Genes and
PDYN Levels in Human Brain
(A) Levels of opioid mRNA in the nucleus accum-
bens (NAc), prefrontal cortex (PFC), and cere-
bellum (Cb) were quantified by TaqMan low-
density arrays in postmortem samples from three
control subjects. PDYN expression was substan-
tially lower in Cb compared to NAc and PFC,
the two brain areas with high and moderate
gene expression. In the Cb, PENK showed high
expression levels compared to the PFC but lower
expression levels compared to the NAc. Both
OPRK1 and OPRM1 are expressed in Cb, NAc,
and PFC at similar levels, whereas OPRD1 expres-
sion was not detectable in the Cb. Data bars
represent the means5 SEM.
(B) Comparison of mRNA levels in the Cb
between three control and SCA23 cerebella. The
data is shown as the ratio of levels in SCA23 to
those in controls. Mean levels in controls were
set to 1, as indicated by the dashed line. PENK, OPRK1, and OPRM1 expression was 2- and 3.5-fold increased, whereas PDYN expression
was slightly decreased in the SCA23 Cb compared to controls.
(C) Analysis of PDYN in the human NAc, PFC, and Cb by immunoblot analysis. Tissue samples were pooled from three control subjects
and purified on SEP-PAC reverse-phase columns prior to SDS-PAGE. PDYN levels in cerebellum are intermediate between those in NAc
and PFC.
(D) No differences were evident between PDYN levels in control (C1-3) and SCA23 cerebella.effects of WT and mutant Dyn A peptides on the viability
of striatal neurons via environmentally controlled time-
lapse imaging. Although mild toxic effects were induced
by WT Dyn A, we observed marked increases in neuro-
nal losses following exposure to p.R212W and p.R215C
mutant Dyn A peptides compared to vehicle-treated con-
trols or the WT peptide after 60 hr of exposure (Figures
2E and 2F). No significant differences in cell viability
were observed between control and the p.L211S Dyn
A-treated neurons. Thus, two mutations in Dyn A may
enhance the intrinsic neurotoxicity of WT Dyn A.
The bias, based almost exclusively on data in mature
rodents, is that the endogenous opioid peptides and
their receptors are not produced and do not regulate neu-
ronal activity in the cerebellum.28 To gain insight into
pathophysiological mechanisms of PDYN actions, we
characterized these systems in three controls and SCA23
cerebella. Only a single brain of a SCA23 PDYN p.R138S
subject was available for postmortem analysis.6 Our
results showed that PDYN was expressed in the human
cerebellum, although at low levels compared to the
nucleus accumbens (NAc) and prefrontal cortex (PFC;
Figure 3A). In contrast to animals, the k- and m- (OPRM1;
MIM #600018) opioid receptors and proenkephalin
(PENK; MIM #131330) were expressed in human cere-
bellum at levels that were comparable with those in the
NAc and PFC, whereas the d-opioid receptor (OPRD1) was
not expressed (Figure 3A).29 In SCA23 tissue, cerebellar
OPRK1, OPRM1, and PENK were 2- to 3.5-fold upregulated,
whereas the level of PDYN mRNA was slightly lower than
in controls (Figure 3B). In contrast to mRNA, cerebellar
PDYN levels were intermediate between those in PFC and
NAc and were similar in controls and SCA23 (Figures 3C
and 3D). The high protein levels in relation to PDYNThe Americanexpression in cerebellum in comparison to NAc and PFC
suggest slower processing of PDYN to mature peptides in
this area.
To determine in which cell types PDYN, Dyn A, and
Dyn B are localized in cerebellum, we performed immuno-
histochemistry. This analysis demonstrated that PDYN and
its major peptide products are mainly located in the Pur-
kinje cells in both control and SCA23 cerebellum (Fig-
ure 4A). The SCA23 cerebellum showed significant loss of
Purkinje cells and atrophic dendrites, as was described
previously.6 No marked differences in the localization
and generation of PDYN and the Dyn A and B peptides
were observed between control and SCA23 cerebella.
Dyn A has been shown to induce neurodegeneration
through a nonopioid mechanism that may involve gluta-
mate receptors and acid-sensing ion channels.9,30 To
unravel cellular pathways affected by PDYN p.R138S, we
performed shotgun proteomic analysis of control and
SCA23 cerebella. Proteins involved in cell adhesion, synap-
togenesis, secretory pathways, and signal transduction
were up- or downregulated in SCA23 (Figure S1 and
Table S4). Key nodemolecules in cellular pathways affected
in SCA23 cerebellum identified by pathway analysis
include enzymes regulating glutamate cycling and pro-
teins involved in neuroprotection, apoptosis, and signal
transduction (Table S5). The solute carrier, SLC1A6 (alias
EAAT4; excitatory amino acid transporter), a marker of
Purkinje cells that has been previously found to be down-
regulated or aggregated in SCA1 and SCA5,31,32 was
decreased in the proteome of SCA23 PDYN p.R138S (Table
S4). Immunoblotting confirmed a reduction in the 65 kDa
EAAT4 in the SCA23 cerebellum by 3-fold (Figure 4B).
About 70% of EAAT4 was accumulated as aggregated or
polyubiquitinated protein in SCA23 (Figure 4C). EAAT4Journal of Human Genetics 87, 593–603, November 12, 2010 599
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Figure 4. Localization of PDYN and Dynorphins, and Analysis of the Purkinje Cell-Specific Excitatory Amino Acid Transporter, in
SCA23 Cerebellum
(A) Immunohistochemistry of cerebellum from the PDYN p.R138S subject and a control individual without neurological disease. Immu-
noperoxidase labeling with anti-Dyn A, anti-Dyn B, or anti-PDYN antibodies was visualized by 3-Amino-9-ethylcarbazole as the chro-
mogen and was counterstained with hematoxylin.
(B) Immunoblot analysis of excitatory amino acid transporter (EAAT4) and calbindin, both Purkinje cell markers. Highmolecular weight
species were detected in the SCA23 cerebellum (*).
(C) Immunoperoxidase labeling of EAAT4 in SCA23 and control cerebellum.
Scale bars represent 30 mm (A and C).showed strong staining in perikarya and dendrites of the
Purkinje cells in control and SCA23 cerebella (Figure 4C).
Calbindin is another protein marker of the Purkinje cells
and was also found to be downregulated in SCA1 and
SCA5 cerebella.31,32 Although the proteomic analysis
showed only marginal 1.6-fold decrease in calbindin levels
in SCA23, further immunoblot analysis demonstrated
substantial 7-fold downregulation of this protein in the
pathological cerebellum (Figure 4B).Discussion
We have shown that missense mutations in PDYN cause
a relatively slowly progressive, cerebellar ataxia with
some distinctive features such as distal sensory neuropathy
and pyramidal signs, proximal paresis of the legs, and
tremors of the head and upper limbs. SCA23 was assumed
to be a relatively pure cerebellar ataxia. However, our find-
ings showed that the clinical phenotype of SCA23 can be
highly variable and that no common starting symptom
was present in our four different SCA23 families. Muta-
tions in PDYN are identified here in a small subset of Dutch
ataxia families (4 of 1100), indicating that SCA23 seems
an infrequent SCA type (50.5%) in the Netherlands and
suggesting further genetic heterogeneity. However, the
syndromes present in our ataxia panel are phenotypically
not well defined, which is reflected in the low success
rate (~20%) to identify mutations in known SCA genes
via diagnostic screening. This may explain why we have
identified only 4 ataxia families exhibiting PDYN muta-600 The American Journal of Human Genetics 87, 593–603, Novembtions in 1100 cases. Although we can only speculate about
the frequency of SCA23 in a phenotypically better-defined
cohort, we assume that SCA23 is a rare cause of ataxia and
will not account for more than ~0.5% of the Dutch ataxia
cases. To exclude the possibility that the PDYN p.R138S
mutation would be a random sequence variation that
cosegregates with the true disease mutation within the
linkage interval, we sequenced 1000 unrelated blood
bank control chromosomes in which this variation was
not observed, and we did not identify any other additional
coding sequence variation in 31 previously sequenced
candidate genes that perfectly cosegregated with the
disease phenotype in this family.7 In two families (PDYN
p.R138S and p.R215C), we could confirm that the muta-
tions segregated with the disease.
The in silico analysis predicts damaging effects of three
Dyn A mutations (p.L211S, p.R212W, and p.R215C) on
protein structure and possibly function, whereas the
p.R138S mutation was assessed as benign. The negative
prediction may be due to the insufficient sensitivity of
the programs used in analysis, because they are based on
similar algorithms and may have the same limitation.
The analysis may also be hindered by the absence of any
structural information for this class of proteins. Formation
of an additional phosphorylation site in PDYN by the
p.R138S mutation may affect processing or trafficking of
mutant protein, thus representing an alternative mecha-
nism of the pathogenic activity of PDYN.
Model cell experiments provided evidence that the
PDYNmutations p.L211S (Leu5) and p.R212W (Arg6) result
in enhanced Dyn A levels. This may be due to slower 12, 2010
conversion of mutant Dyn A to short enkephalins. Indeed,
conversion of Dyn A to short fragments generally occurs
at di- and monobasic amino acid residues, including Leu5
and Arg9, that are substituted by Ser and Cys in mutant
PDYN.23 In addition, analysis of the effect of mutant
Dyn A peptides on striatal neurons demonstrated high
toxicity of Dyn A p.R212W and Dyn A p.R215C. The
elevated neurotoxicity of Dyn A mutants compared to
WT Dyn A suggests a dominant-negative effect of these
mutations rather than a loss of function. The increased
stabilization of the mutant Dyn A peptides may not be
the only factor underlying neurotoxicity, because Dyn A
p.L211S, which is apparently resistant for conversion to
a short fragment, does not induce any toxic response.
Immunohistochemical experiments revealed that PDYN,
Dyn A, and Dyn B are mainly located in the Purkinje cells
in both control and SCA23 cerebella. The absence of sig-
nificant differences in PDYN and dynorphin localization
and PDYN levels between control and PDYN p.R138S cere-
bella, observed by both the cell staining and immunoblot-
ting, further argues against a possible loss of function and
suggests that PDYN is strongly elevated in the Purkinje cells
remaining in SCA23.
Further analysis of the endogenous opioid systems and
the proteome in cerebellar autopsy tissue of the PDYN
p.R138S subject revealed marked alterations in expression
of crucial components of the opioid and glutamate sys-
tems. These alterations were evident for OPRM1, OPRK1,
enzymes regulating glutamate cycling, and the excitatory
amino acid transporter, EAAT4. These findings are consis-
tent with previous observations demonstrating alterations
in expression and localization of EAAT4 in SCA1 and SCA5
cerebella and provide additional evidence for the hypoth-
esis that the dysfunction of glutamate signaling is a com-
mon downstream mechanism for SCA.31,32
Two putative mechanisms may be envisaged to explain
the pathogenic effects of mutant PDYNs. First, modifica-
tions of nonopioid neurodegenerative and/or opioid activ-
ities of Dyn A or its longer pathological form, such as the
32 amino acid big dynorphin, may lead to alterations
in glutamate signaling and excitotoxicity.9,26,30,33 Several
lines of evidence support this notion. Thus, Dyn A,
but not other dynorphins, elicits various pathological
effects, including neurological dysfunction and cell death.
Intracerebroventricular injection of this peptide induces
abnormal motor effects such as wild running, barrel roll-
ing, and ataxia in mice, whereas intrathecal infusion
produces allodynia, paralysis, and neuronal loss.9,34–39
Consistently, increased production of Dyn A following
trauma contributes to spinal cord injury and neuro-
pathic pain.9,37–39 Dyn A is also upregulated in aging
rodent brain, contributing to age-related impairment of
spatial learning and memory.40 In the prefrontal cortex
of Alzheimer disease patients, the elevated Dyn A levels
correlate with neuritic plaque density.41 Second, synthesis
of mutant PDYNs may affect secretory pathways, inducing
endoplasmic reticulum stress and impairing maturationThe Americanand trafficking of glutamate transporters and other sig-
naling proteins. Actions of mutant PDYNs accumulating
over the years may ultimately lead to Purkinje cell degener-
ation. The p.R138S mutation located in the nonopioid
PDYN domain supports the second hypothesis.
Neuropeptides are a large group of signaling molecules
that regulate a wide variety of physiological and patholog-
ical processes.9,10 A mutation that causes early-onset
obesity and adrenal insufficiency had been found in proo-
piomelanocortin, the protein precursor to adrenocortico-
tropin, a-melanocyte-stimulating hormone, and b-endor-
phin.42 Our findings demonstrate that mutations in a
neuropeptide gene may cause an inherited neurodegener-
ative disorder. Neuropeptides usually exert their actions
as ligands of G protein-coupled receptors. In the case of
Dyn A, although physiological effects are largely mediated
through the k-opioid receptors, pathological effects may be
generally mediated through direct action of this peptide
on the plasma membrane, possibly by inducing pore
formation and increased calcium influx in neurons.9,43–45
Remarkably, three mutations identified in SCA23 families
alter the amino acid sequence of Dyn A in a domain asso-
ciated with non-receptor-mediated, neurodegenerative
actions. Two peptides with these mutations cause signifi-
cant toxicity in cultured neurons, raising the possibility
that some SCA23 degenerative processes are due to direct
effects of mutant peptides on neurons. We may speculate
that mutations in other neuropeptide precursor genes
are involved in the etiology of cerebellar ataxia and
that their identification will provide further insight
into mechanisms of synaptic neurotransmission and
neurodegeneration.Supplemental Data
Supplemental Data include one figure and eight tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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